Spyre Therapeutics (SYRE) Interest Expenses (2015 - 2026)
Spyre Therapeutics (SYRE) posted Interest Expenses of $1.1 million for Q1 2026, up 811.21% on a QoQ basis from $116000.0 in Q4 2025, and up 556.52% year-over-year from $161000.0 in Q1 2025.
Spyre Therapeutics (SYRE) Interest Expenses (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Interest Expenses history runs 12 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- Quarterly Interest Expenses rose 556.52% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 556.52% YoY) and the FY2025 annual result came in at $201.3 million, up 23.58% from the prior year.
- Interest Expenses was $1.1 million for Q1 2026 at Spyre Therapeutics, up from $116000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $162.9 million in Q4 2024 and bottomed at $20000.0 in Q3 2024.
- A 5-year average of $19.5 million and a median of $161000.0 in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses soared 65947.89% — and 2025, when it slumped 99.93%.
- Spyre Therapeutics' Interest Expenses stood at $190000.0 in 2022, then surged by 65947.89% to $125.5 million in 2023, then rose by 29.83% to $162.9 million in 2024, then slumped by 99.93% to $116000.0 in 2025, then surged by 811.21% to $1.1 million in 2026.
- Business Quant data shows SYRE's Interest Expenses at $1.1 million in Q1 2026, $116000.0 in Q4 2025, and $38000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 32.89 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 16.81 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.17 Bn |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | 1.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.06 Mn |
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 116,000.00 |
| Dec 31, 2025 | 116,000.00 |
| Sep 30, 2025 | 38,000.00 |
| Sep 30, 2025 | 38,000.00 |
| Jun 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 153,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | 162.93 Mn |
| Dec 31, 2024 | 162.93 Mn |
| Sep 30, 2024 | 20,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 673,000.00 |
| Jun 30, 2024 | 673,000.00 |
| Mar 31, 2024 | 451,000.00 |
| Mar 31, 2024 | 451,000.00 |
| Dec 31, 2023 | 125.49 Mn |
| Dec 31, 2023 | 125.49 Mn |